+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors



Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors



Pharmacology 88(1-2): 1-9



The present study was designed to investigate the effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (atorvastatin, pravastatin, simvastatin) on the pharmacokinetics of losartan and its active metabolite EXP-3174 in rats. Pharmacokinetic parameters of losartan and EXP-3174 in rats were determined after oral and intravenous administration of losartan (9 mg/kg) without and with HMG-CoA reductase inhibitors (1 mg/kg). The effect of HMG-CoA reductase inhibitors on P-gp and cytochrome (CYP) 3A4 activity were also evaluated. Atorvastatin, pravastatin and simvastatin inhibited CYP3A4 activities with IC₅₀ values of 48.0, 14.1 and 3.10 μmol/l, respectively. Simvastatin (1-10 μmol/l) enhanced the cellular uptake of rhodamine-123 in a concentration-dependent manner. The area under the plasma concentration-time curve (AUC₀₋∞) and the peak plasma concentration of losartan were significantly (p < 0.05) increased by 59.6 and 45.8%, respectively, by simvastatin compared to those of control. The total body clearance (CL/F) of losartan after oral administration with simvastatin was significantly decreased (by 34.8%) compared to that of controls. Consequently, the absolute bioavailability (F) of losartan after oral administration with simvastatin was significantly increased by 59.4% compared to that of control. The metabolite-parent AUC ratio was significantly decreased by 25.7%, suggesting that metabolism of losartan was inhibited by simvastatin. In conclusion, the enhanced bioavailability of losartan might be mainly due to inhibition of P-gp in the small intestine and CYP3A subfamily-mediated metabolism of losartan in the small intestine and/or liver and to reduction of the CL/F of losartan by simvastatin.

(PDF emailed within 0-6 h: $19.90)

Accession: 052848811

Download citation: RISBibTeXText

PMID: 21709429

DOI: 10.1159/000328773


Related references

Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. Pharmacological Reports 67(1): 44-51, 2016

Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats. Die Pharmazie 68(11): 882-888, 2014

Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin. Journal of Pharmacy and Pharmacology 62(7): 908-914, 2011

Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin. Pharmacological Reports 63(6): 1574-1582, 2012

Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174. International Journal of Clinical Pharmacology and Therapeutics 50(9): 683-689, 2013

Role of CYP3A4 and P-glycoprotein in drug interactions involving the HMG-CoA reductase inhibitors. Journal of the American Pharmaceutical Association 41(1): 5-6, 2001

HPLC assays to stimultaneously determine the angiotensin-AT1 antagonist losartan as well as its main and active metabolite EXP 3174 in biological material of humans and rats. Journal of Pharmaceutical & Biomedical Analysis 16(5): 863-873, 1998

Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin. Die Pharmazie 67(2): 124-130, 2012

Similarities and differences in the inhibition of rat lens aldose reductase and kidney aldehyde reductase by aldose reductase inhibitors. Investigative Ophthalmology & Visual Science 30(3 SUPPL): 193, 1989

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clinical Pharmacology and Therapeutics 71(1): 89-98, 2002

In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. European Journal of Clinical Pharmacology 50(3): 209-215, 1996

A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metabolism and Disposition: the Biological Fate of Chemicals 29(3): 282-288, 2001

Role of aldose reductase and effects of aldose reductase inhibitors in ocular tissue aging phenomena in the diabetic rat. Armstrong, D , M F Marmor And J M Ordy (Ed ) The Effects Of Aging And Environment on Vision; American Aging Association Symposium on Environmental Design For Optimum Vision in The Elderly, San Francisco, California, Usa, October 11-12, 1985 Viii+231p Plenum Press: New York, New York, Usa; London, Englannd, Uk Illus 121-131, 1991

Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers. European Journal of Clinical Pharmacology 65(6): 585-591, 2009

Pharmacokinetics of losartan and its active carboxylic acid metabolite E-3174 in five ethnic populations of China. Journal of Clinical Pharmacy and Therapeutics 37(2): 226-231, 2012